Compare GSHD & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GSHD | ANIP |
|---|---|---|
| Founded | 2003 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 2018 | N/A |
| Metric | GSHD | ANIP |
|---|---|---|
| Price | $66.17 | $81.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 6 |
| Target Price | $95.73 | ★ $107.33 |
| AVG Volume (30 Days) | 259.3K | ★ 548.1K |
| Earning Date | 02-23-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 68.12 | N/A |
| EPS | 1.14 | ★ 1.67 |
| Revenue | $353,231,000.00 | ★ $826,880,000.00 |
| Revenue This Year | $16.89 | $44.35 |
| Revenue Next Year | $18.89 | $11.13 |
| P/E Ratio | $56.34 | ★ $48.66 |
| Revenue Growth | 25.01 | ★ 48.87 |
| 52 Week Low | $59.53 | $54.10 |
| 52 Week High | $127.99 | $99.50 |
| Indicator | GSHD | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 43.06 | 49.82 |
| Support Level | $59.53 | $78.79 |
| Resistance Level | $66.26 | $83.80 |
| Average True Range (ATR) | 2.79 | 2.63 |
| MACD | -0.10 | -0.11 |
| Stochastic Oscillator | 43.86 | 41.54 |
Goosehead Insurance Inc operates as an insurance agency. Its insurance products consist of homeowner's insurance; auto insurance; other personal lines products including flood, wind and earthquake insurance; excess liability or umbrella insurance; specialty lines insurance (motorcycle, recreational vehicle and other insurance); commercial lines insurance (general liability, property, and auto insurance for small businesses); and life insurance. Geographically, it operates in Texas, California, Illinois, Florida, and other regions.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.